- Home
- ICLR
ICLR
ICON plc
as of 11-04-2026 4:00pm EST
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
| Founded: | 1990 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 13.1B | IPO Year: | 2001 |
| Target Price: | $231.29 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $66.57 - $219.04 | Next Earning Date: | 10-27-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -1.05% | Revenue Growth (next year): | 4.60% |
| P/E Ratio: | 12.91 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -10.66% |
AI-Powered ICLR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ICON plc (ICLR)
Chief Executive Officer
Avg Cost/Share
$207.15
Shares
5,175
Total Value
$1,069,441.17
Owned After
11,904
Director
Avg Cost/Share
$205.67
Shares
3,452
Total Value
$709,955.58
Owned After
17,000
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$207.15
Shares
1,488
Total Value
$307,502.81
Owned After
7,922
Chief Accounting Officer
Avg Cost/Share
$207.15
Shares
264
Total Value
$54,557.74
Owned After
1,288
Chief Accounting Officer
Avg Cost/Share
$182.39
Shares
272
Total Value
$49,603.67
Owned After
1,288
Director
Avg Cost/Share
$175.00
Shares
5,005
Total Value
$875,875.00
Owned After
3,847
SEC Form 4
Director
Avg Cost/Share
$175.00
Shares
3,255
Total Value
$569,625.00
Owned After
3,811
SEC Form 4
Director
Avg Cost/Share
$175.00
Shares
5,005
Total Value
$875,875.00
Owned After
2,087
SEC Form 4
Director
Avg Cost/Share
$164.12
Shares
841
Total Value
$138,168.80
Owned After
6,916
Director
Avg Cost/Share
$164.12
Shares
915
Total Value
$150,326.22
Owned After
3,588
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Balfe Barry Edward | ICLR | Chief Executive Officer | Nov 2, 2026 | Sell | $207.15 | 5,175 | $1,069,441.17 | 11,904 | |
| Murray Ciaran | ICLR | Director | Nov 2, 2026 | Sell | $205.67 | 3,452 | $709,955.58 | 17,000 | |
| Clerkin Nigel Bernard John | ICLR | Chief Financial Officer | Nov 2, 2026 | Sell | $207.15 | 1,488 | $307,502.81 | 7,922 | |
| Lyons Emer | ICLR | Chief Accounting Officer | Nov 2, 2026 | Sell | $207.15 | 264 | $54,557.74 | 1,288 | |
| Lyons Emer | ICLR | Chief Accounting Officer | Oct 23, 2026 | Sell | $182.39 | 272 | $49,603.67 | 1,288 | |
| Murphy Ronan Martin | ICLR | Director | Sep 17, 2026 | Sell | $175.00 | 5,005 | $875,875.00 | 3,847 | |
| McCague Eugene Pacelli | ICLR | Director | Sep 17, 2026 | Sell | $175.00 | 3,255 | $569,625.00 | 3,811 | |
| CLIMAX JOHN DR | ICLR | Director | Sep 16, 2026 | Sell | $175.00 | 5,005 | $875,875.00 | 2,087 | |
| Grais Linda | ICLR | Director | Aug 11, 2026 | Sell | $164.12 | 841 | $138,168.80 | 6,916 | |
| O'Neill Julie | ICLR | Director | Aug 11, 2026 | Sell | $164.12 | 915 | $150,326.22 | 3,588 |
Compare ICLR vs Leading Stocks
See how ICLR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ICLR ICON plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.